HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

AbstractBACKGROUND:
Botanical therapies are often used by breast cancer patients yet few clinical trials have evaluated their safety and efficacy. We studied mechanisms of activity and performed a phase I clinical trial in patients with advanced breast cancer to evaluate BZL101, an aqueous extract from Scutellaria barbata.
METHODS:
Preclinical studies were conducted in vitro to characterize cell death induced by BZL101. In a phase I trial, eligible patients had histologically confirmed, measurable metastatic breast cancer. Treatment consisted of 350 ml per day of oral BZL101, administered as sole cancer therapy until disease progression, toxicity or personal preference to discontinue. Primary endpoints were safety, toxicity and tumor response.
RESULTS:
BZL101 extract induced strong growth inhibition and apoptosis of breast cancer cell lines. In the phase I trial, 21 patients received BZL101. Mean age was 54 years (30-77) and mean number of prior treatments for metastatic disease was 3.9 (0-10). There were no grade III or IV adverse events (AEs). The most frequently reported BZL101-related grade I and II AEs included: nausea (38%), diarrhea (24%), headache (19%) flatulence (14%), vomiting (10%), constipation (10%), and fatigue (10%). Sixteen patients were evaluable for response. Four patients had stable disease (SD) for >90 days (25%) and 3/16 had SD for >180 days (19%). Five patients had objective tumor regression, one of which was 1 mm short of a PR based on RECIST criteria.
CONCLUSIONS:
BZL 101 inhibits breast cancer cell lines by inducing apoptosis. In a phase I clinical trial, BZL101 was safe and had a favorable toxicity profile. BZL101 demonstrated encouraging clinical activity in this heavily pretreated population.
AuthorsHope Rugo, Emma Shtivelman, Alejandra Perez, Charles Vogel, Sandra Franco, Elizabeth Tan Chiu, Michelle Melisko, Mary Tagliaferri, Isaac Cohen, Mark Shoemaker, Zung Tran, Debu Tripathy
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 105 Issue 1 Pg. 17-28 (Sep 2007) ISSN: 0167-6806 [Print] Netherlands
PMID17111207 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Plant Extracts
  • Scutellaria barbata extract
  • Caspases
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage, pharmacology)
  • Apoptosis
  • Breast Neoplasms (drug therapy)
  • Caspases (metabolism)
  • Cell Line, Tumor
  • DNA Fragmentation
  • Enzyme Activation
  • Female
  • Flow Cytometry (methods)
  • Humans
  • Middle Aged
  • Plant Extracts (administration & dosage, pharmacology)
  • Scutellaria (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: